Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
These findings indicate that although plasma and CSF neurogranin may reflect the volume of acute cerebral ischemia, this synaptic protein is less likely to be a potential AIS biomarker.
-
This study evaluated performance of a commercially available standardized software program for calculation of florbetapir PET standard uptake value ratios (SUVr) in comparison with an established research method.
-
Neuropathological studies have shown that the typical neurofibrillary pathology of hyperphosphorylated tau protein in Alzheimer’s disease (AD) preferentially affects specific brain regions whereas others remain relatively spared.
-
Future longitudinal studies examining the association of more severe depressive symptoms and cerebral tau accumulation are needed to substantiate this finding and to guide prevention and treatment in AD.
-
Co-existence of Alzheimer's disease (AD) in normal pressure hydrocephalus (NPH) is a frequent finding, thus a common pathophysiological basis between AD and NPH has been postulated.
-
We investigated the frequency of Lewy-related pathology (LRP) in the amygdala among the population-based Vantaa 85+ study.
-
MCI-AD patients yielded larger P50s than MCI-Other.
-
Different clinical variants of probable Alzheimer's disease (AD) share underlying plaques and tangles but show distinct atrophy patterns.
-
48/100
The need for effective treatments halting Alzheimer's disease (AD) urges the discovery of the earliest possible biomarkers.
-
After correction for age, sex, and education, CSF tau levels were found to be negatively related to the Visual Association Test (standardized β = -0.3, P < .05), whereas CSF Aβ1-42 levels were found to be positively related to the Mini-Mental State Examination (β = 0.3, P < .05), the frontal assessment battery (β = 0.5, P < .05), and digit span backwards test (β = 0.3, P = .01).
-
There is an urgent need for biomarkers in plasma to identify Alzheimer's disease (AD).
-
Diagnosis of the progressive neurodegenerative disorder Alzheimer's disease (AD) can only definitively be made postmortem.
-
It is possible to create a blood-based screening algorithm that works across both serum and plasma that provides a comparable screening accuracy to that obtained from CSF analyses.
-
An ideal diagnostic test for Alzheimer's disease (AD) should be non-invasive and easily applicable.
-
Biomarkers are urgently needed for the diagnosis and monitoring of disease progression in Parkinson's disease.
-
We used an autopsy series to determine whether the newest dementia with Lewy bodies (DLB) consensus pathologic classification correlates with premortem diagnosis of DLB.
-
Evidence supports an important role for beta-amyloid (Abeta) in the pathogenesis of Alzheimer's disease (AD).
-
We conducted virus-isolation studies on 56 specimens from the nervous system of 45 patients in order to determine whether human T-cell lymphotropic virus Type III (HTLV-III) is directly involved in the pathogenesis of the neurologic disorders frequently encountered in the acquired immunodeficiency syndrome (AIDS) and the AIDS-related complex.
-
Monoclonal antibodies targeting amyloid-β are the first approved disease-modifying treatment for Alzheimer’s disease.
-
Alzheimer's disease involves a drastic departure from the cognitive, functional, and behavioural trajectory of normal ageing, and is both a dreaded and highly prevalent cause of disability to individuals, and a leading source of health and social care expenditure for society.
-
Antiamyloid antibodies have been used to reduce cerebral amyloid-beta (Aβ) load in patients with Alzheimer's disease.
-
Plasma P-tau181 effectively detects Aβ+ status and conversion to dementia, confirming the value of this blood biomarker for the management of AD.
-
Blood-based tests have sparked tremendous attention in non-invasive early diagnosis of Alzheimer's disease (AD), a most prevalent neurodegenerative malady worldwide.
-
47/100
Lecanemab can be administered without titration with modest incidence of ARIA.
-
Clinical prediction models combining plasma biomarkers-particularly p-tau217-exhibit high performance and are less effected by random error.
From across this topic
10 of the 1,573 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Optimized dual-time-window protocols for quantitative [18F]flutemetamol and [18F]florbetaben PET studies
- Plasma tau biomarkers for biological staging of Alzheimer's disease
- Chemically treated plasma Aβ is a potential blood-based biomarker for screening cerebral amyloid deposition
- Does CSF testing add value after an indeterminate plasma p-tau217 result?
- Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities
- Tau Accumulation in Clinically Normal Older Adults Is Associated with Hippocampal Hyperactivity
- Anti-Amyloid Therapy, AD, and ARIA: Untangling the Role of CAA
- Serum p-tau217 Is a Prognostic Indicator of Cognitive Impairment in Idiopathic REM Sleep Behavior Disorder
- The application of retinal fundus camera imaging in dementia: A systematic review
- Biomarkers of dementia in obstructive sleep apnea